I. Gazi

发表

Orlistat-Associated Adverse Effects and Drug Interactions

D. Mikhailidis, M. Elisaf, T. Filippatos, 2008, Drug safety.

M. Elisaf, I. Gazi, E. Bairaktari, 2008, NMR in biomedicine.

Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia

D. Mikhailidis, M. Elisaf, T. Filippatos, 2007, Current Medical Research and Opinion.

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin

S. Daskalopoulou, D. Mikhailidis, I. Gazi, 2007, Current medical research and opinion.

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview

D. Mikhailidis, I. Gazi, 2006, Expert opinion on therapeutic targets.

Increased plasma visfatin levels in subjects with the metabolic syndrome

M. Elisaf, T. Filippatos, I. Gazi, 2007, European journal of clinical investigation.

Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.

M. Elisaf, I. Gazi, A. Tambaki, 2005, Prostaglandins, leukotrienes, and essential fatty acids.

Rosuvastatin Increases α‐1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia

H. Milionis, M. Kostapanos, M. Elisaf, 2006 .

Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress

M. Kostapanos, E. Liberopoulos, M. Elisaf, 2011, Lipids.

Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia.

M. Kostapanos, M. Elisaf, T. Filippatos, 2010, Atherosclerosis.

LDL cholesterol estimation in patients with the metabolic syndrome

M. Elisaf, T. Filippatos, I. Gazi, 2006, Lipids in Health and Disease.

The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia

J. Papadakis, D. Mikhailidis, I. Gazi, 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome.

M. Elisaf, I. Gazi, R. Kalaitzidis, 2006, Metabolic syndrome and related disorders.

Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

D. Mikhailidis, H. Milionis, M. Kostapanos, 2006, Current medical research and opinion.

Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome

M. Elisaf, T. Filippatos, D. Mikhailidis, 2008, Lipids.

Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2

R. Wolfert, M. Kostapanos, M. Elisaf, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women

H. Milionis, M. Kostapanos, M. Elisaf, 2008, Diabetes/metabolism research and reviews.

Effect of infection on lipid profile: focus on Epstein–Barr virus

M. Elisaf, I. Gazi, 2010 .

there is evidence that an increased (pathogen burden) may interact with other factors and lead to the appearance or progression of atherosclerotic disease.

I. Gazi, 2010 .

Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes.

E. Liberopoulos, M. Elisaf, I. Gazi, 2010, Atherosclerosis.

Starting with Rosuvastatin in Primary Hyperlipidemia—

H. Milionis, J. Goudevenos, M. Elisaf, 2005, Angiology.

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

E. Liberopoulos, M. Elisaf, T. Filippatos, 2007, Atherosclerosis.

The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study.

K. Kotani, N. Sakane, M. Elisaf, 2012, Metabolism: clinical and experimental.

Persistence of an atherogenic lipid profile after treatment of acute infection with brucella

M. Elisaf, I. Gazi, A. Tselepis, 2009, Journal of Lipid Research.

Visceral leishmaniasis is associated with marked changes in serum lipid profile

E. Liberopoulos, M. Elisaf, I. Gazi, 2014, European journal of clinical investigation.

The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome

E. Liberopoulos, M. Elisaf, M. Florentin, 2012, Archives of medical science : AMS.

Leptospirosis is Associated with Markedly Increased Triglycerides and Small Dense Low-Density Lipoprotein and Decreased High-Density Lipoprotein

E. Liberopoulos, M. Elisaf, T. Filippatos, 2011, Lipids.

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

D. Mikhailidis, I. Gazi, 2006, Diabetes Care.

Lipids in Health and Disease

M. Elisaf, T. Filippatos, I. Gazi, 2006 .

Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2004 .

High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid.

M. Elisaf, A. Kyritsis, I. Gazi, 2012, European journal of dermatology : EJD.

Plasma Lipoproteins and Triacylglycerol are Predictors of Small, Dense LDL Particles

M. Elisaf, I. Gazi, A. Tselepis, 2007, Lipids.

Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease

J. Papadakis, N. Tzanakis, D. Mikhailidis, 2007, International journal of clinical practice.

Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia

D. Mikhailidis, I. Gazi, E. Ganotakis, 2009, The open cardiovascular medicine journal.

: Is There More Than Lipid Lowering? -- Starting with Rosuvastatin in Primary Hyperlipidemia

H. Milionis, J. Goudevenos, M. Elisaf, 2013 .

Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation.

J. Papadakis, D. Mikhailidis, I. Gazi, 2007, In vivo.

Beneficial effects of omega-3 fatty acids: the current evidence.

E. Liberopoulos, M. Elisaf, I. Gazi, 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins.

D. Mikhailidis, E. Ganotakis, I. Gazi, 2007, Clinical and experimental rheumatology.

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.

M. Elisaf, T. Filippatos, D. Mikhailidis, 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

D. Mikhailidis, M. Elisaf, I. Gazi, 2007, Expert opinion on biological therapy.

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

M. Elisaf, T. Filippatos, I. Gazi, 2005, Clinical chemistry.

The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome

M. Kostapanos, M. Elisaf, T. Filippatos, 2008, Diabetes, obesity & metabolism.

Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study

M. Elisaf, T. Filippatos, D. Mikhailidis, 2013, Archives of medical science : AMS.

Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria.

M. Elisaf, T. Filippatos, I. Gazi, 2006, Metabolism: clinical and experimental.

Statins and solid organ transplantation.

E. Liberopoulos, M. Elisaf, D. Mikhailidis, 2006, Current pharmaceutical design.

The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2006, Lipids.

Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes

M. Elisaf, T. Filippatos, I. Gazi, 2013, Lipids.

LDL-cholesterol calculation formulas in patients with or without the metabolic syndrome.

M. Elisaf, I. Gazi, 2007, International journal of cardiology.

Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia.

H. Milionis, M. Kostapanos, M. Elisaf, 2006, Journal of clinical pharmacology.

Visceral leishmaniasis is associated with marked changes in serum lipid profile

E. Liberopoulos, M. Elisaf, I. Gazi, 2014, European journal of clinical investigation.

LDL cholesterol estimation in patients with the metabolic syndrome

M. Elisaf, T. Filippatos, I. Gazi, 2006, Lipids in Health and Disease.